Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolterodine vs oxybutynin for daytime sleepiness in obstructive sleep apnea
IRCT20160926029976N7Phase 3Completed
- Sponsor
- Babol University of Medical Sciences
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of tolterodine and oxybutynin in obstructive sleep apnea hypopnea syndrome (OSAHS) (2 arms), sponsored by Babol University of Medical Sciences. Primary endpoint: Daytime sleepiness. Started Nov 2025; status: completed.
02
Drugs
tolterodineoxybutynin
03
Conditions
obstructive sleep apnea hypopnea syndrome (OSAHS)
Beyond the preview
Go deeper on IRCT20160926029976N7.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20160926029976N7.